Hytenza CO

Hytenza Co® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan (Hytenza Co) and Hydrochlorothiazide (Hytenza Co).

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.

Hytenza Co may be administered with other antihypertensive agents.


Hytenza Co contains a combination of Hytenza Co. Hydrochlorothiazide (Hytenza Co) is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention. Losartan (Hytenza Co) is an angiotensin II receptor antagonist. Losartan (Hytenza Co) keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.

Hytenza Co is used to treat high blood pressure (hypertension). It is also used to lower the risk of stroke in certain people with heart disease.

Hytenza Co may also be used for purposes not listed in this medication guide.


Always take Hydenza Co exactly as your doctor has instructed you.

The usual starting and maintenance dose is one Hytenza Co 50/12,5 tablet once daily for most patients. for patients who do not respond adequately, the dosage may be increased to two Hytenza Co 50/12,5 tablets once daily.

More about the product

Each tablet contains:

Losartan (Hytenza Co) potassium 50mg and Hydrochlorothiazide (Hytenza Co) 12.5 mg.